Pancreatic Enzyme Product Activity Steps Up As NDA Deadline Approaches

With the NDA submission deadline for previously unregulated pancreatic enzyme products less than a year away, the exocrine pancreatic insufficiency market is heating up as manufacturers of pig-derived products seek to stay on the market and a non-porcine alternative noses closer to submission